NCT01337921

Brief Summary

The aims are to 1) compare two probiotic treatments (multi-strain synbiotic vs. multi-strain probiotic) on bifidobacteria fecal colonization counts at 1, 2, 3, and 4 weeks of life, 34 weeks corrected gestation age (CGA) ; 2) compare infants successfully colonized with probiotic organisms to infants not successfully colonized at 1, 2, 3, and 4 weeks of life, 34 weeks CGA on infant outcomes and on stress biomarker patterns at birth, day of life (DOL) 1, DOL 7; 3) determine long-term safety and outcomes of probiotic treatments at 6, 16, and 24 months CGA.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2011

Shorter than P25 for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 16, 2011

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 19, 2011

Completed
1 month until next milestone

Study Start

First participant enrolled

June 1, 2011

Completed
15 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 16, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 16, 2011

Completed
Last Updated

August 14, 2023

Status Verified

August 1, 2023

Enrollment Period

15 days

First QC Date

March 16, 2011

Last Update Submit

August 10, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Comparing a multi-strain synbiotic vs. a multi-strain probiotic on mean bifidobacteria fecal colonization counts

    Infants will be given the synbiotic or probiotic supplementation within the first week of life (upon inititation of enteral feedings) until approximately 34 weeks corrected gestational age.

    1,2, 3, 4 and 34 weeks of age

Secondary Outcomes (5)

  • Compare the difference between two groups (multi-strain synbiotic vs. multi-strain probiotic) on demographic data and selected standard clinical infant outcomes.

    From birth to NICU discharge (average 36 weeks corrected gestational age)

  • Compare the difference between infants successfully colonized with probiotic organisms (>10^2 colonies on a 10^4-fold dilution plate)to infants not successfully colonized on demographics and selected standard clinical outcomes

    1 week of life to NICU discharge

  • Compare infants successfully colonized with probiotic organisms(>10^2 colonies on a 10^4-fold dilution plate) to infants not successfully colonized on stress biomarker levels

    day of life 1 to day of life 7

  • Compare trends of stress biomarker levels in relation to demographics and selected standard infant outcomes

    day of life 1 to day of life 7

  • Compare the difference between the two probiotic treatment groups (multi-strain synbiotic vs. multi-strain probiotic) on longitudinal neurodevelopmental outcomes.

    6, 16 & 24 months corrected gestational age.

Study Arms (2)

Multi-strain Synbiotic

EXPERIMENTAL

Multi-strain probiotic with prebiotics

Dietary Supplement: Multi-strain Probiotic

Multi-strain Probiotic

ACTIVE COMPARATOR

Multi-strain Probiotic without prebiotics.

Dietary Supplement: Multi-strain Probiotic

Interventions

Multi-strain ProbioticDIETARY_SUPPLEMENT

Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)

Also known as: Lactobacillus
Multi-strain ProbioticMulti-strain Synbiotic

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • infants with a birth weight \< 1500g
  • admission to NICU at The Nebraska Medical Center

You may not qualify if:

  • infants who have congenital anomalies
  • have a diagnosis of a congenital metabolic disease
  • are made a ward of the State or
  • are born to a mother \< 19 years of age

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Enterocolitis, Necrotizing

Interventions

Lacteol

Condition Hierarchy (Ancestors)

EnterocolitisGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Study Officials

  • Ann Anderson-Berry, MD

    University of Nebraska

    STUDY CHAIR
  • Corrine K Hanson, PhD

    UNMC

    STUDY CHAIR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 16, 2011

First Posted

April 19, 2011

Study Start

June 1, 2011

Primary Completion

June 16, 2011

Study Completion

June 16, 2011

Last Updated

August 14, 2023

Record last verified: 2023-08